Goutham Sunny: AdvanTIG-202 Trial – A Breakthrough in R/M Cervical Cancer
Goutham Sunny, Former Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X about a paper by Jung-Yun Lee et al. published in Gynecologic Oncology:
“AdvanTIG-202 Trial: A breakthrough in recurrent/metastatic cervical cancer (R/M CC)!
Combo: Ociperlimab (anti-TIGIT) + Tislelizumab (anti-PD-1)
Patients: R/M CC, post-chemo, not eligible for curative treatment
1st study of immune checkpoint combo in R/M CC regardless of PD-L1 status
Results (Cohort 1):
ORR:
- PD-L1+: 27.4%
- All-comers: 23.2%
Better than historical anti-PD1 response (~15%)
- PFS: 3.0 mo (all), 4.1 mo (PD-L1+)
- OS: 12.2 mo (all), 16.4 mo (PD-L1+)
Drawbacks:
- TRAEs in 70.3%
- Grade ≥3 AEs in 18.1%
- Immune AEs in 35.5%
Significance:
- Promising efficacy in a high-need population
- Supports future trials of immune-modulating combos in R/M CC
- May expand options beyond PD-L1+ patients!”
Title: AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer
Authors: Jung-Yun Lee, Sathana Boonyapipat, Guangwen Yuan, Hee Seung Kim, Jeong-Won Lee, Li Wang, Tao Wang, Danbo Wang, Desheng Yao, Hu Liu, Chih-Long Chang, Timur Turdeevich Andabekov, Xiang Zhang, Wei Wang, Yong Man Kim, Ivan Volodymyrovych Sinielnikov, Kai Wang, Yujuan Gao, Xiyan Mu, Lingying Wu
You can read the Full Article in Gynecologic Oncology.
More posts featuring Goutham Sunny.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023